Skip to content
Haloperidol decanoate
Haldol (haloperidol decanoate) is a small molecule pharmaceutical. Haloperidol decanoate was first approved as Haldol on 1982-01-01. It is used to treat child behavior disorders, psychotic disorders, schizophrenia, schizophrenia spectrum and other psychotic disorders, and substance withdrawal syndrome amongst others in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A, D(4) dopamine receptor, D(3) dopamine receptor, and D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 7, histamine H1 receptor, D(1A) dopamine receptor, 5-hydroxytryptamine receptor 1D, D(1B) dopamine receptor, potassium voltage-gated channel subfamily H member 1, and G protein-activated inward rectifier potassium channel 2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
hereditary congenital and neonatal diseases and abnormalitiesD009358
signs and symptoms pathological conditionsD013568
chemically-induced disordersD064419
mental disordersD001523
Trade Name
FDA
EMA
Haldol (generic drugs available since 1986-06-10, discontinued: Haldol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Haloperidol
Tradename
Company
Number
Date
Products
HALDOLJohnson & JohnsonN-015921 DISCN1982-01-01
6 products, RLD
HALDOL SOLUTABJohnson & JohnsonN-017079 DISCN1982-01-01
1 products
Hide discontinued
Haloperidol decanoate
Tradename
Company
Number
Date
Products
HALDOLJohnson & JohnsonN-018701 RX1986-01-14
2 products, RLD, RS
Haloperidol lactate
Tradename
Company
Number
Date
Products
HALDOLJohnson & JohnsonN-015923 DISCN1982-01-01
1 products, RLD
HALDOLJohnson & JohnsonN-015922 DISCN1982-01-01
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
haldol decanoateNew Drug Application2020-11-24
haloperidol decanoateANDA2023-06-07
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
child behavior disorders—D002653—
psychotic disorders—D011618F20.81
schizophreniaEFO_0000692D012559F20
schizophrenia spectrum and other psychotic disorders—D019967—
substance withdrawal syndromeEFO_0005800D013375—
tourette syndromeEFO_0004895D005879F95.2
vomitingHP_0002013D014839R11.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05A: Antipsychotics
— N05AD: Butyrophenone derivatives, antipsychotics
— N05AD01: Haloperidol
HCPCS
Code
Description
J1631
Injection, haloperidol decanoate, per 50 mg
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OsteosarcomaD01251622———4
NeoplasmsD009369C8012——24
LymphomaD008223C85.922———3
SarcomaD012509—1———1
MucositisD052016EFO_100189811———1
Hematologic neoplasmsD01933711———1
Drug-related side effects and adverse reactionsD064420T88.7—1———1
Large b-cell lymphoma diffuseD016403C83.3—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938C951————1
Kidney diseasesD007674EFO_0003086N081————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHALOPERIDOL DECANOATE
INNhaloperidol
Description
Haloperidol decanoate is an organic molecular entity.
Classification
Small molecule
Drug classantipsychotics (haloperidol type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1
Identifiers
PDB—
CAS-ID74050-97-8
RxCUI26420
ChEMBL IDCHEMBL1200986
ChEBI ID—
PubChem CID52919
DrugBankDBSALT001195
UNII IDJ6292F8L3D (ChemIDplus, GSRS)
Target
Agency Approved
HTR2A
HTR2A
DRD4
DRD4
DRD3
DRD3
DRD2
DRD2
Organism
Homo sapiens
Gene name
HTR2A
Gene synonyms
HTR2
NCBI Gene ID
3356
Protein name
5-hydroxytryptamine receptor 2A
Protein synonyms
5-HT2 receptor, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, serotonin 5-HT-2A receptor, Serotonin receptor 2A
Uniprot ID
Q5T8C0
Mouse ortholog
Htr2a (15558)
5-hydroxytryptamine receptor 2A (P35363)
Alternate
HTR1A
HTR1A
HTR2B
HTR2B
HTR7
HTR7
HRH1
HRH1
DRD1
DRD1
HTR1D
HTR1D
DRD5
DRD5
KCNH1
KCNH1
KCNJ6
KCNJ6
Organism
Homo sapiens
Gene name
HTR1A
Gene synonyms
ADRB2RL1, ADRBRL1
NCBI Gene ID
3350
Protein name
5-hydroxytryptamine receptor 1A
Protein synonyms
5-HT1a receptor, 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled, G-21, guanine nucleotide-binding regulatory protein-coupled receptor, Serotonin receptor 1A
Uniprot ID
Q6LAE7
Mouse ortholog
Htr1a (15550)
5-hydroxytryptamine receptor 1A (Q8BGS4)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 28,626 documents
View more details
Safety
Black-box Warning
Black-box warning for: Haldol decanoate, Haloperidol decanoate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
222 adverse events reported
View more details